Brendan D Connealy1, Hope Northrup2, Kit Sing Au3. 1. Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Medicine, University of Texas Medical School at Houston, Houston, TX. Electronic address: brendan.d.connealy@uth.tmc.edu. 2. Division of Medical Genetics, Department of Pediatrics, University of Texas Medical School at Houston, Houston, TX; Shriners Hospital for Children, Houston, TX. 3. Division of Medical Genetics, Department of Pediatrics, University of Texas Medical School at Houston, Houston, TX.
Abstract
OBJECTIVE: Our objectives were to examine the extent of described sequence variation in the glucose transporter 3 (GLUT3) gene in children with myelomeningocele (MM), identify novel variations in the GLUT3 gene in these children, and determine whether these variations may confer a risk of MM. STUDY DESIGN: We sequenced the 10 exons of GLUT3, including exon-intron boundaries, on 96 children with MM. Sequencing was performed with Sanger methods and results analyzed with deoxyribonucleic acid analysis software. Frequencies of known single-nucleotide polymorphisms were identified, and those differing from the reference sequence (GRCh37/hg19 assembly) were considered variations. RESULTS: Six novel and 9 previously described, genetic variations were identified in our population. The novel variations included a large, 83 base pair deletion involving the core promoter region and part of exon 1 (1 of 96 children), and a 2 base pair deletion in the coding sequence of exon 4 (1 of 96 children). The remaining novel variations were located in the introns in the proximity of the splice sites. Novel mutations in GLUT3 were observed among 6.25% of our population. Additionally, the frequency of the rare allele for rs17847972 located in a splice donor site is higher (P < .001) in MM in our population than expected. CONCLUSION: We identified previously undescribed deletions and single-nucleotide variations involving the GLUT3 gene that may be associated with increased susceptibility to MM. Of particular interest, the 2 deletions involve both an important core promoter site and a coding region predicted to have a deleterious effect. The functional significance of these findings is under investigation.
OBJECTIVE: Our objectives were to examine the extent of described sequence variation in the glucose transporter 3 (GLUT3) gene in children with myelomeningocele (MM), identify novel variations in the GLUT3 gene in these children, and determine whether these variations may confer a risk of MM. STUDY DESIGN: We sequenced the 10 exons of GLUT3, including exon-intron boundaries, on 96 children with MM. Sequencing was performed with Sanger methods and results analyzed with deoxyribonucleic acid analysis software. Frequencies of known single-nucleotide polymorphisms were identified, and those differing from the reference sequence (GRCh37/hg19 assembly) were considered variations. RESULTS: Six novel and 9 previously described, genetic variations were identified in our population. The novel variations included a large, 83 base pair deletion involving the core promoter region and part of exon 1 (1 of 96 children), and a 2 base pair deletion in the coding sequence of exon 4 (1 of 96 children). The remaining novel variations were located in the introns in the proximity of the splice sites. Novel mutations in GLUT3 were observed among 6.25% of our population. Additionally, the frequency of the rare allele for rs17847972 located in a splice donor site is higher (P < .001) in MM in our population than expected. CONCLUSION: We identified previously undescribed deletions and single-nucleotide variations involving the GLUT3 gene that may be associated with increased susceptibility to MM. Of particular interest, the 2 deletions involve both an important core promoter site and a coding region predicted to have a deleterious effect. The functional significance of these findings is under investigation.
Authors: Amit Ganguly; Robert A McKnight; Santanu Raychaudhuri; Bo-Chul Shin; Zhigui Ma; Kelle Moley; Sherin U Devaskar Journal: Am J Physiol Endocrinol Metab Date: 2007-01-09 Impact factor: 4.310
Authors: Jack M Fletcher; Kim Copeland; Jon A Frederick; Susan E Blaser; Larry A Kramer; Hope Northrup; H Julia Hannay; Michael E Brandt; David J Francis; Grace Villarreal; James M Drake; John P Laurent; Irene Townsend; Susan Inwood; Amy Boudousquie; Maureen Dennis Journal: J Neurosurg Date: 2005-04 Impact factor: 5.115
Authors: Eric R Detrait; Timothy M George; Heather C Etchevers; John R Gilbert; Michel Vekemans; Marcy C Speer Journal: Neurotoxicol Teratol Date: 2005-03-05 Impact factor: 3.763
Authors: Christina M Davidson; Hope Northrup; Terri M King; Jack M Fletcher; Irene Townsend; Gayle H Tyerman; Kit Sing Au Journal: Reprod Sci Date: 2008-01 Impact factor: 3.060
Authors: Z J Hagay; Y Weiss; I Zusman; M Peled-Kamar; E A Reece; U J Eriksson; Y Groner Journal: Am J Obstet Gynecol Date: 1995-10 Impact factor: 8.661
Authors: Bo-Chul Shin; Carlos Cepeda; Ana María Estrada-Sánchez; Michael S Levine; Laya Hodaei; Yun Dai; Jai Jung; Amit Ganguly; Peter Clark; Sherin U Devaskar Journal: J Neurosci Date: 2018-09-19 Impact factor: 6.167